Transcription of YERVOY U.S. Prescribing Information - BMS
{{id}} {{{paragraph}}}
Example: bankruptcy
YERVOY U.S. Prescribing Information - BMS
HIGHLIGHTS OF Prescribing Information Advanced renal cell carcinoma: These highlights do not include all the Information needed to use YERVOY safely Nivolumab 3 mg/kg administered intravenously over 30 minutes followed by and effectively. See full Prescribing Information for YERVOY . YERVOY (ipilimumab) 1 mg/kg administered intravenously over 30 minutes on the same day, every 3 weeks for 4 doses, then nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks, administered intravenously over 30 minutes. ( ). YERVOY (ipilimumab) injection, for intravenous use Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic Initial Approval: 2011 colorectal cancer: Nivolumab 3 mg/kg followed by YERVOY 1 mg/kg on the same day every 3 weeks for 4 doses, then nivolumab 240 mg every 2 weeks ( ).
The recommended dosages of YERVOY as a single agent are presented in Table 1. Table 1: Recommended Dosages for YERVOY as a Single Agent Indication Recommended YERVOY Dosage Duration of Therapy Unresectable or metastatic melanoma 3 mg/kg every 3 weeks 30-minute intravenous infusion Maximum of 4 doses Adjuvant treatment of melanoma
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: